Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06970301 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
A Phase 1 study of Healthy Study Participants, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06970301 is a Phase 1 study of Healthy Study Participants that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06970301, a Phase 1 study of Healthy Study Participants, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG glovadalen
Study Locations (1)
California
- Up0135 1001 - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06970301
The ClinicalTrials.gov registry entry for NCT06970301 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Study Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06970301 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06970301 about?
NCT06970301 is a clinical study titled "A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants". The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
What is the current status of trial NCT06970301?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-04-28. Estimated completion is 2026-05-29.
What conditions does trial NCT06970301 study?
This clinical trial studies the following conditions: Healthy Study Participants.
What interventions are being tested in trial NCT06970301?
The interventions under investigation include: Placebo (OTHER), glovadalen (DRUG).
Who is sponsoring clinical trial NCT06970301?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06970301 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Study Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
COMPLETED · Phase 1
-
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.